LON:ROQ Roquefort Therapeutics (ROQ) Share Price, News & Analysis GBX 1.63 +0.08 (+5.03%) As of 11:10 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesBuy This Stock About Roquefort Therapeutics Stock (LON:ROQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Roquefort Therapeutics alerts:Sign Up Key Stats Today's Range 1.55▼ 1.8450-Day Range 1.40▼ 1.8852-Week Range 1.32▼ 6.78Volume2.84 million shsAverage Volume2.42 million shsMarket Capitalization£2.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRoquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.Read More… Receive ROQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ROQ Stock News HeadlinesSMALL-CAP WINNERS & LOSERS: Roquefort jumps on Oncogeni dealMarch 10, 2025 | lse.co.ukRoquefort Therapeutics CEO resigns, agrees terms for Oncogeni disposalMarch 10, 2025 | lse.co.uk“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.May 28, 2025 | Brownstone Research (Ad)SMALL CAP IDEA: Roquefort finds pharma diamonds in the roughFebruary 10, 2025 | msn.comRoquefort Therapeutics proposes USD10 million subsidiary saleJanuary 2, 2025 | lse.co.ukGlycoMimetics, Inc. (GKO.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comRoquefort Therapeutics says MK cell therapy patent approved in JapanSeptember 24, 2024 | lse.co.ukTG Therapeutics, Inc. (TGTX)August 10, 2024 | finance.yahoo.comSee More Headlines ROQ Stock Analysis - Frequently Asked Questions How have ROQ shares performed this year? Roquefort Therapeutics' stock was trading at GBX 4.10 on January 1st, 2025. Since then, ROQ shares have decreased by 60.3% and is now trading at GBX 1.63. View the best growth stocks for 2025 here. How were Roquefort Therapeutics' earnings last quarter? Roquefort Therapeutics plc (LON:ROQ) announced its quarterly earnings data on Wednesday, April, 30th. The company reported ($0.75) earnings per share for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative trailing twelve-month return on equity of 29.57%. How do I buy shares of Roquefort Therapeutics? Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Roquefort Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roquefort Therapeutics investors own include Vislink Technologies (XGTI), AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX) and Abacus Health Products (ABAHF). Company Calendar Last Earnings4/30/2025Today5/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ROQ CIKN/A Webwww.roquefortinvest.com Phone44 20 3290 9339FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£1.52 million Net Margins-57,057.07% Pretax MarginN/A Return on Equity-29.57% Return on Assets-15.86% Debt Debt-to-Equity Ratio12.37 Current Ratio0.79 Quick Ratio3.07 Sales & Book Value Annual Sales£2,662.35 Price / Sales778.15 Cash FlowGBX 1.09 per share Price / Cash Flow1.49 Book ValueGBX 3.82 per share Price / Book0.43Miscellaneous Outstanding Shares127,254,864Free FloatN/AMarket Cap£2.07 million OptionableNot Optionable Beta0.05 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (LON:ROQ) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.